Cartesian Therapeutics Announces New Employment Inducement Grants
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotechnology company focused on mRNA cell therapies for autoimmune diseases, has granted inducement awards to three new employees. On January 2, 2025, the company issued options to purchase a total of 19,324 shares of common stock at an exercise price of $16.93 per share, matching the closing price on Nasdaq that day.
The options were granted under the company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and approved by the board. The vesting schedule includes 25% on January 2, 2026, followed by three equal annual installments until full vesting on January 2, 2029. The options have a ten-year term and were granted under Nasdaq Rule 5635(c)(4) as employment inducements.
Details
News Market Reaction – RNAC
The recorded move for RNAC in the trading session of this news was -2.67%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FREDERICK, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to three new employees. On January 2, 2025, the Company issued to these employees options to purchase an aggregate of 19,324 shares of the Company’s common stock with an exercise price of
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com
Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.